Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3283142 PK in Hepatic Impairment
NCT06402721Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAY3283142 in chronic kidney disease (CKD) (3 arms), sponsored by Bayer. Primary endpoints: Area under the curve at Day 6 and Maximum observed drug concentration at Day 6. Started May 2024; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06402721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06402721.